Innovative Medicine Backed by the Power of Artificial Intelligence

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology.

About Us

Company’s Approach to Drug Development

Company’s Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology programs utilize our AI approach to drug development.

BXCL501

BXCL501 is an investigational, proprietary, orally dissolving, thin film formulation of dexmedetomidine designed for the treatment of agitation and opioid withdrawal symptoms.

BXCL701

BXCL701 is an investigational, orally-administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Latest News

BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

View Release

BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia

View Release

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

View Release
View all news

Sign up for Email Alerts

Email Sign Up

Stock Information

BioXcel Therapeutics, Inc.

View Investor Relations View Investor Presentation